Actinogen Gets Third DMC Green Light for XanaMIA as November Topline Nears

Actinogen Medical (ASX: ACW) said its pivotal XanaMIA Alzheimer’s trial has received a third positive recommendation from the independent Data Monitoring Committee (DMC), which advised the study continue without amendment.

The update reduces near-term safety-related interruption risk ahead of the planned November 2026 topline readout, but it does not answer the central efficacy question for Xanamem.

In practical terms, a DMC recommendation to continue unchanged means the committee did not identify safety issues requiring protocol changes, a pause or another immediate intervention based on the data it reviewed.

The committee assessed safety data across all 247 participants enrolled in XanaMIA, giving this review broad coverage of the ongoing study population.

That matters more than an earlier checkpoint because the trial is now fully recruited and closed to new enrolment.

The immediate significance is trial continuity.

The company’s filing supports the study proceeding on its current plan, while the question of whether Xanamem 10mg once daily can outperform placebo on the main outcome measure remains reserved for the final topline dataset.

XanaMIA Trial Background

Before today’s update, it is worth stepping back to what XanaMIA is.

This is Actinogen’s Phase 2b/3 pivotal study of oral Xanamem in patients with mild to moderate Alzheimer’s disease across Australia and the US. T

he trial is designed as double-blind, placebo-controlled and parallel group, with patients receiving 10mg once daily over 36 weeks.

The primary endpoint is CDR-SB, or Clinical Dementia Rating Scale Sum of Boxes, a commonly used measure intended to track changes in cognition and function in Alzheimer’s disease.

Because CDR-SB is the main test of whether the drug is having a meaningful effect, that endpoint remains the central issue for the investment case and the program’s regulatory future.

Central to Strategy

This study sits at the centre of Actinogen’s current Alzheimer’s strategy.

In earlier filings, the company said both FDA discussions and European Medicines Agency (EMA) scientific advice pointed to a development pathway in which XanaMIA would be followed by one additional well-controlled pivotal Phase 3 trial, subject to results from the current study.

The company has also already opened XanaMIA-OLE, an open-label extension launched in March 2026.

Under that extension, eligible former and current participants can receive active Xanamem 10mg once daily for up to 25 months.

Actinogen has said the extension is intended to add longer-term safety and observational efficacy information, but because it does not include a placebo arm, it is not a substitute for the randomised pivotal data.

Review Details and Numbers

According to today’s announcement, the DMC reviewed safety data for all 247 trial participants, including more than 100 patients who had completed the full 36 weeks of treatment.

Oral Xanamem continues to demonstrate a “promising safety profile” in mild to moderate Alzheimer’s disease patients treated up to 36 weeks.

The filing frames that as a safety and tolerability observation, not as evidence that the drug has met its efficacy objective.

Unlike the January 2026 DMC meeting, this latest review was not asked to assess unblinded efficacy in a prespecified interim analysis.

That means the latest recommendation should be read as a safety-based clearance to continue, rather than a fresh signal on whether the drug is working against placebo.

The company did not announce any protocol changes, increase in trial size or shift in the timetable.

Recruitment remains closed, and the expected timing for final topline results remains November 2026.

What to Watch Next

The next major milestone is still the November 2026 topline result from XanaMIA, which is expected to determine whether Xanamem shows a benefit on CDR-SB versus placebo in the 247-patient randomised study.

Beyond that first readout, the regulatory path remains important.

In May 2026, Actinogen said the EMA had provided positive scientific advice broadly aligned with prior FDA guidance.

According to that filing, the pathway in Alzheimer’s disease contemplates one additional pivotal Phase 3 trial using 10mg versus placebo after XanaMIA, plus a limited number of ancillary clinical pharmacology trials and some nonclinical work on safety, metabolism and excretion.

There is also the open-label extension to monitor.

XanaMIA-OLE could add longer-duration safety observations over as much as 25 months, and Actinogen has said those data may support future marketing applications.

Even so, the extension is observational and lacks a placebo control, so its evidentiary weight is inherently different from the main randomised study.

Safety Cleared, Efficacy Still Pending

Today’s announcement strengthens the case that Actinogen can carry XanaMIA through to its planned data readout without a safety-driven protocol change.

But the decisive issue for the program remains unchanged: whether Xanamem can outperform placebo on CDR-SB when topline results are reported in November 2026, and whether that is strong enough to support the next regulatory step.

In short, today’s filing narrows one near-term risk by supporting uninterrupted trial conduct.

The unresolved issues are still clinical and regulatory: whether the pivotal dataset can show efficacy on CDR-SB, whether that result is strong enough to support the next development step, and whether Actinogen can carry the program through the required follow-on work after the first readout.